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The feasibility of a randomised controlled 
trial to compare the cost-effectiveness 
of palliative cardiology or usual care in 
people with advanced heart failure: Two 
exploratory prospective cohorts
Miriam J Johnson1 , Paula McSkimming2, Alex McConnachie2, 
Claudia Geue3, Yvonne Millerick4, Andrew Briggs5  
and Karen Hogg6
Abstract
Background: The effectiveness of cardiology-led palliative care is unknown; we have insufficient information to conduct a full trial.
Aim: To assess the feasibility (recruitment/retention, data quality, variability/sample size estimation, safety) of a clinical trial of 
palliative cardiology effectiveness.
Design: Non-randomised feasibility.
Setting/participants: Unmatched symptomatic heart failure patients on optimal cardiac treatment from (1) cardiology-led palliative 
service (caring together group) and (2) heart failure liaison service (usual care group).
Outcomes/safety: Symptoms (Edmonton Symptom Assessment Scale), Kansas City Cardiomyopathy Questionnaire, performance, 
understanding of disease, anticipatory care planning, cost-effectiveness, survival and carer burden.
Results: A total of 77 participants (caring together group = 43; usual care group = 34) were enrolled (53% men; mean age 77 years 
(33–100)). The caring together group scored worse in Edmonton Symptom Assessment Scale (43.5 vs 35.2) and Kansas City 
Cardiomyopathy Questionnaire (35.4 vs 39.9). The caring together group had a lower consent/screen ratio (1:1.7 vs 1: 2.8) and few 
died before approach (0.08% vs 16%) or declined invitation (17% vs 37%).
Data quality: At 4 months, 74% in the caring together group and 71% in the usual care group provided data. Most attrition was due 
to death or deterioration. Data quality in self-report measures was otherwise good.
Safety: There was no difference in survival. Symptoms and quality of life improved in both groups. A future trial requires 141 
(202 allowing 30% attrition) to detect a minimal clinical difference (1 point) in Edmonton Symptom Assessment Scale score for 
breathlessness (80% power). More participants (176; 252 allowing 30% attrition) are needed to detect a 10.5 change in Kansas City 
Cardiomyopathy Questionnaire score (80% power; minimum clinical difference = 5).
Conclusion: A trial to test the clinical effectiveness (improvement in breathlessness) of cardiology-led palliative care is 
feasible.
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Introduction
Compared with people with cancer, those with advanced 
heart failure have equivalent palliative care needs with 
poorer access to specialist palliative care.1–6 Palliative care 
is recommended,7–10 but poorly implemented.11–15
Phase III trials of specialist palliative care for people with 
heart failure16–19 report cost-effective20,21 benefit with spe-
cialist palliative care without compromising survival. 
However, most palliative concerns in people with heart fail-
ure can be managed by the usual care team using a patient-
centred approach with access to specialist palliative care for 
complex issues only.22,23 Previous integrated service descrip-
tions do not include patient-reported outcomes,24–27 and the 
effectiveness of cardiology-led palliative care is untested.
A partnership between two charities (Marie Curie and 
British Heart Foundation) and a Scottish NHS health board 
developed cardiology-led models of heart failure palliative 
care (‘The Caring Together (CT) Programme’28).
The study objectives were to assess the feasibility of a 
future randomised controlled trial (RCT) in terms of (1) 
recruitment/retention, (2) data quality, (3) variability/sam-
ple size estimation and (4) safety.
Methods
Expanded methods are available online.
Study design
This prospective feasibility cohort single-site study (data 
collection at baseline, 2 and 4 months) used two heart 
failure outpatient groups. The participants continued 
2 monthly measures until the last recruit completed 
4 months’ follow-up.
Ethical (NRES Committee London – Camberwell St 
Giles. REF 14/LO/1813; 07.10.2014) and institutional 
approvals were obtained prior to recruitment. The partici-
pants gave written informed consent.
Participants
Participants were adults with symptomatic heart failure 
(reduced or normal left ventricular ejection fraction; 
HFrEF, HFnEF) and family carers. Participants with at 
least one CT clinic attendance formed the caring together 
group (CTG). A convenience unmatched usual care group 
(UCG) was formed from heart failure liaison nurse service 
patients fulfilling CT criteria but who had not been referred. 
The risk of contamination was deemed to be minimal.29
Caring together intervention
Box 1 shows the referral criteria and components. 
Collaborative primary and secondary care is led by a con-
sultant cardiologist and a heart failure palliative care nurse 
consultant, through a palliative cardiology multi-discipli-
nary team (MDT).
Usual care
The liaison nurse service and other consultant cardiologists’ 
clinics provide education, self-care promotion, medical ther-
apy up-titration and patient/family support (HFrEF only).
What is already known about the topic?
•• Compared with people with cancer, those with advanced heart failure have equivalent palliative care needs with poorer 
access to specialist palliative care.
•• A palliative care approach led by cardiology teams and access to specialist palliative care according to need rather than 
prognosis is recommended but poorly implemented.
•• The evidence base for palliative care in heart failure is less robust than that for cancer and there are no published pro-
spectively collected data for cardiology-led palliative care services.
What this paper adds?
•• Novel prospectively collected data for cardiology-led palliative care services which show that a future trial of cardiology-
led palliative care is feasible in terms of recruitment to a clinical study (note: willingness to randomisation was not 
tested), data quality and sample size.
•• Data generating a hypothesis that cardiology-led palliative care may safely improve advance care planning and patients’ 
understanding of their condition, enable care at home and reduce costs.
Implications for practice, theory or policy
•• Findings should be tested in an adequately powered randomised controlled trial.
•• Future studies should identify and randomise patients with more severe or complex palliative care needs to ensure 
optimal use of finite specialist palliative care resources.
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Study measures
1. Recruitment: screen-to-consent ratio, reasons for 
non-consent, recruitment rate, retention.
2. Data quality of protocol measures.
(a) Demographic and clinical measures at baseline: 
New York Heart Association (NYHA) status;30 
Australian-modified Karnofsky Performance 
Status (AKPS);31 Charlson et al.’s32 comorbid-
ity index; medication-optimised cardiac treat-
ment; pulse, heart rate, presence/absence of 
oedema and jugular venous pressure; urea and 
electrolytes; and echocardiogram (HFrEF and 
HFnEF; for HFrEF, ‘mild, moderate, severe’, 
ejection fraction).
(b) Patient measures at baseline and follow-up: 
AKPS, Edmonton Symptom Assessment 
Scale – revised (ESAS-r),33 Kansas City 
Cardiomyopathy Questionnaire (KCCQ-12),34–
36 EuroQol EQ-5D-5L,37 Hospital Anxiety and 
Depression Scale (HADS),38 patient under-
standing (Likert), health service utilisation 
and costs (including medication) and Zarit 6 
caregiver burden (carers).39
(c) Clinical measures at baseline and follow-up: 
survival, clinical documentation of anticipa-
tory care planning (ACP).
3. Candidate primary outcome data variability for 
power estimation.
4. Safety: survival (6 months) and outcomes 
(4 months).
Data were not collected on willingness to be 
randomised.
Statistical analysis
Data are presented using descriptive statistics. Sample size 
estimations were conducted based on variability data 
around candidate primary outcomes.
Safety assessment: (1) Cox proportional hazards mod-
els were used for between-group survival differences and 
(2) Group 4 month outcomes comparison by study entry 
group used two-sample t tests (continuous) and Fisher’s 
exact tests (categorical), unless otherwise stated. No 
adjustments were made for multiple comparisons. Missing 
data were not imputed. A ‘per-protocol’ (PP) repeated-
measures model analysis excluded UCG participants 
referred to CT. Two random-effects repeated-measures 
regression models with (1) the KCCQ-12 and (2) the 
EQ-5D-5L, as the dependent outcomes adjusted for age, 
sex and baseline ESAS-r scores, were used. The estimated 
between-group differences were reported with 95% confi-
dence intervals (CIs) and p values. PP analysis was com-
pleted for the initial repeated-measures model (data 
available).
Incremental costs and outcomes associated with CTG 
were determined. Resource use items included health ser-
vice utilisation and medication. Analyses were conducted 
using SAS for Windows version 9.3. Formal power calcu-
lation was inappropriate.
Results
A total of 77 participants (43 CTG and 34 UCG) were 
recruited (8 April to 18 December 2015). A follow-up of 
4 months is presented except for the repeated-measures 
model, survival and health service utilisation (8 months) 
and study flow (10 months).
Box 1. Caring together components (adapted, Caring Together Manualisation Report, 2014).28
I. Patient identification and referral
•• Diagnosis of heart failurea (NYHA III or IV).
•• Distressing or debilitating symptoms despite optimal medical therapy.
Supportive or palliative care needs (physical, social, emotional, spiritual or psychological).
II. Holistic assessment
•• Cardiology review.
•• Holistic assessment: review with patient and carer needs, identification of individually tailored solutions.
III. Care management and coordination
•• Care manager assigned (usually heart failure nurse specialist) as the main contact for care management, information, 
advice and support.
IV. Training and education
•• Training provided to stakeholders delivering services within the programme.
•• Shared learning between specialties (palliative care/cardiology and service delivery settings, community/acute care).
V. Multi-disciplinary work and joint working
•• Joint working and care coordination across teams (community, out-of-hours care, acute care): problems identified 
during the holistic assessment may trigger referral to other agencies or other MDT members, including primary care.
•• Care manager coordinates care with the MDT and actions additional referrals if required.
•• Individually tailored medical anticipatory care plan (MACP), including tailored anticipated medical interventions, such as 
cardiopulmonary resuscitation status decisions, device management and place of care/death shared with all members of 
the healthcare team including out-of-hours teams and specialist palliative care as needed.
aPatients with reduced or normal left ventricular function are eligible.
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Feasibility measures
Table 1 shows the patient flow. One UCG participant con-
sented for every 2.8 screened versus 1 per 1.4 CTG 
screened. Fewer in the CTG died before approach (0.08% 
vs 16%) or declined invitation (17% vs 37%).
Most attrition was due to death or deterioration; those 
providing follow-up data had better performance status, 
symptom scores and quality of life (QoL) at baseline 
(data available). Data quality was otherwise good (Tables 
2 and 3).
Baseline characteristics
Both groups were on optimal tolerated cardiac treatment.
There were clinically important between-group differ-
ences (Tables 4 and 5). Nearly all UCG participants had 
HFrEF, but half of the CTG participants had HFnEF 
(Table 4). CTG patients had worse NYHA class, symp-
toms (ESAS-r) and quality of life (KCCQ-12), and less 
deprivation. Most CTG participants had ACP documented 
and better understanding.
More UCG participants had prior admissions (47.1% vs 
32.6%). All CTG participants had attended CT at least 
once (median: 8 months; inter-quartile range (IQR): 
2–21 months).
Group comparison at follow-up
Overall, the ESAS-r and KCCQ-12 scores improved. At 
4 months, adjusted symptom improvement was greater in 
the UCG (0.046). ACP documentation and understanding 
remained better in the CTG (p < 0.001). Two UCG partici-
pants were transferred to CTG, but there were no differ-
ences in the PP analysis findings.
CTG participants had fewer nights in hospital, but more 
GP visits (eTable 1). CT participants commented on excel-
lent, individually tailored, coordinated care. UCG partici-
pants commented on fragmented care, poor communication 
and different unfamiliar doctors.
There was no between-group difference in survival 
(eFigure 1 online; time to death).
Repeated-measures model
There were no between-group differences in EQ-5D-5L 
(p = 0.50) or KCCQ-12 (p = 0.08) at 4 months after adjust-
ment for age, sex or baseline individual ESAS-r (eFigure 2 
online).
Health service use and costs
Differences in health service use are shown in eTable 1. 
Estimated differences in costs show that the average 
healthcare costs reduced by £785 in CTG. This is statisti-
cally insignificant and subject to considerable uncertainty.
Sample size calculation for the main trial
Important clinical differences for KCCQ-1240 and ESAS 
(breathlessness)41 were used. UCG was taken as the popu-
lation of interest and ESAS (breathlessness) as the symp-
tom most highly correlated with KCCQ-12 (data available). 
eTable 2 shows the estimated sample sizes (80% and 90% 
power; alpha 0.05). To detect a difference of 10.5 points 
(KCCQ-12) and 1 point (ESAS breathlessness), the sam-
ple sizes of 176 and 141, respectively, are needed (30% 
attrition; 252 and 202).
Discussion
Feasibility outcomes
It is feasible to recruit and collect data for a clinical study. 
As reported previously in palliative studies,42 attrition was 
high (27% at 4 months) mostly due to death or deteriora-
tion. Further feasibility work should test the willingness to 
be randomised.
Table 1. Patient flow.
CTG, n (%) UCG, n (%)
Screening 62 94
 Declined 11 (17) 35 (37)
 Died before approach 5 (0.08) 15 (16)
 Unable to consent 0 4
 Admitted to hospital 1 3
 Other 2 2
Baseline 43/62 (69) 34/94 (36)
Attrition following baseline
 Died 4 2
 Withdrew consent 1 0
 Deterioration 1 2
 Failed to attend 1 0
2-month follow-up 36/43 (84) 30/34 (88)
Attrition following 2 months
 Died 2 1
 Withdrew consent 0 2
 Deterioration 2 0
 Failed to attend 0 1
4-month follow-up 32/43 (74) 24/34 (71)
Longer term follow-up for those recruited earlier in the study
 6-month follow-up 19 8
 8-month follow-up 11 5
Patient status at 10-month follow-up
 Attended 1 0
 Died 9 5
 Withdrew consent 3 4
 Not possiblea 29 25
 Lost to follow up 1 0
CTG: caring together group; UCG: usual care group.
*Patients recruited later in the study would not have sufficient follow-
up time to complete visits beyond 4 months after the recruitment date.
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Strengths and limitations
This the first study to provide patient report and cost-
effectiveness data from a cardiology-led palliative heart 
failure service. Other studies report the components only 
(ACP, patient-centred decisions)43 or historical controls.27
The major limitations are as follows: (1) non-randomi-
sation, (2) cost neutrality was assumed and opportunity 
costs were not considered, (3) missing data and (4) CT par-
ticipants were already receiving cardiology-led palliative 
care (possible underestimated benefit).
Table 2. Outcomes at 4 months.
Values at 4 months Change from baseline at 4 months
CTG, N = 32 UCG, N = 24 P value CTG, N = 32 UCG, N = 24 P value
Health status and QoL
 MD, n 0 0 – 0 0 –
 AKPS, median (IQR) 65 (60, 70) 60 (60, 70) 0.790** 0 (0, 0) 0 (–10, 0) 0.687**
 MD, n 2 1 – 2 1 –
 EQ-5D, mean (SD) 0.586 (0.227) 0.663 (0.250) 0.255 0.1 (0.2) 0.1 (0.3) 0.385*
MD, n 2 0 – 2 0 –
EQ-5D VAS, mean (SD) 56.2 (22.0) 61.7 (23.6) 0.386 3.5 (28.6) –4.0 (22.6) 0.901*
KCCQ-12 score, mean (SD) 42.25 (21.71) 52.92 (24.40) 0.068 5.7 (20.3) 12.4 (25.2) 0.064*
Symptoms
 ESAS-r score, mean (SD) 39.23 (16.84) 28.09 (17.51) 0.022 −1.5 (14.8) −5.6 (16.6) 0.046*
 MD, n 3 0 – 3 0 –
 HADS–anxiety, mean (SD) 5.7 (4.3) 4.0 (5.4) 0.232 −2.0 (3.6) −3.3 (3.7) 0.103*
 HADS–depression, mean (SD) 6.8 (4.3) 5.8 (4.3) 0.408 −0.5 (3.8) −0.5 (4.1) 0.679*
Caregivers
 Caregivers, n (MD) 14 (1) 2 (3) – 14 (1) 2 (3) –
 Zarit caregiver, mean (SD) 10.7 (6.4) 3.5 (2.1) 0.027 0.1 (3.1) –4.0 (2.8) 0.106*
CTG: caring together group; UCG: usual care group; QoL: quality of life; MD: missing data; SD: standard deviation; N: number; IQR: inter-quartile 
range; AKPS: Australian Karnofsky Performance Scale; EQ-5D: EuroQol-5 dimension scale; ESAS-r: Edmonton Symptom Assessment Scale – revised; 
KCCQ-12: Kansas City Cardiomyopathy Questionnaire; HADS: Hospital Anxiety and Depression Scale.
*Adjusted for baseline; **Wilcoxon–Mann–Whitney test.
Table 3. Outcomes at 4 months regarding understanding and anticipatory care planning.
CTG, N = 32 UCG, N = 24 P value
Understanding and anticipatory care planning
Missing data (excluding drop-outs) 2 0 –
Patients’ understanding of care, n (%) <0.001*
 Not at all 0 (0.0) 0 (0.0)  
 A little 4 (13.3) 11 (45.8)  
 Fairly well 9 (30.0) 10 (41.7)  
 Very well 15 (50.0) 3 (12.5)  
 Completely 2 (6.7) 0 (0.0)  
Missing data (excluding drop-outs), n 0 0 –
DNAR-CPR: Evidence of discussion with patient in case notes, n (%) 28 (77.8) 7 (24.1) <0.001
DNAR-CPR: Evidence of discussion with carer in case notes, n (%) 21 (58.3) 4 (13.8) <0.001
CARE: Evidence of discussion with carer in case notes, n (%) 29 (80.6) 9 (31.0) <0.001
CARE: Evidence of discussion with patient in case, n (%) 23 (63.9) 4 (14.3) <0.001
Documented preferred place of carea, n (%) 0.184
 Home 24 (82.8) 6 (66.7)  
 Care home 0 (0.0) 1 (11.1)  
 Hospital 5 (17.2) 2 (22.2)  
 Hospice 0 (0.0) 0 (0.0)  
CTG: caring together group; UCG: usual care group; MD: missing data; N: number; DNAR-CPR: do not attempt cardiopulmonary resuscitation.
aNumber (%) of those who provided a response to this question (CTG: n = 29; UCG: n = 9).
*Wilcoxon–Mann–Whitney test.
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Table 4. Baseline demographic characteristics.
All patients, N = 77 CTG, N = 43 UCG, N = 34 P value
MD 0 0 0 –
Age in years, mean (SD)
Range
77.0 (11.9)
33–100
75.8 (12.3)
33–100
78.4 (11.3)
54–96
0.339
Gender: male, n (%) 41 (53.2) 24 (55.8) 17 (50.0) 0.651
SIMD quintiles; MD, n 2 2 0  
Most deprived, n (%) 27 (36.0) 12 (29.3) 15 (44.1) 0.564
2 9 (12.0) 7 (17.1) 2 (5.9)  
3 9 (12.0) 5 (12.2) 4 (11.8)  
4 8 (10.7) 6 (14.6) 2 (5.9)  
Least deprived 4 (5.3) 2 (4.9) 2 (5.9)  
Hospital admissions
  Admitted due to HF within the past 
6 months, n (%)
30 (39.0) 14 (32.6) 16 (47.1) 0.242
  Admitted to hospital in the past 
1 month, n (%)
11 (14.3) 4 (9.3) 7 (20.6) 0.199
  Number of nights in hospital in the 
past 1 month, n (SD)
6.3 (22.1) 4.5 (21.0) 8.6 (23.6) 0.429
NYHA status, n (%)
 Class I 0 (0.0) 0 (0.0) 0 (0.0) 0.067*
 Class II 3 (3.9) 0 (0.0) 3 (8.8)  
 Class III 70 (90.9) 40 (93.0) 30 (88.2)  
 Class IV 4 (5.2) 3 (7.0) 1 (2.9)  
Echocardiography
 Echo available, n (%) 62 (80.5); 32 (74.4) 30 (88.2) 0.156
 Echo LVSD, n (%) 45 (72.6) 16 (50.0) 29 (96.7) <0.001
 Ejection fraction; MD, n 21 15 6 –
 Mean, % (SD) 42.1 (16.4) 46.5 (19.4) 37.6 (11.3) 0.041
Urea and electrolytes
 Sodium; MD, n 1 1 0 –
 Mean, mmol/l (SD)
Range
139 (3.3)
130–148
138 (3.9)
130–148
139 (2.5)
134–144
0.323
 Potassium; MD, n 2 2 0  
 Mean, mmol/l (SD)
Range
4.2 (0.4)
3.0–5.1
4.2 (0.4)
3.0–5.1
4.3 (0.5)
3.2–5.1
0.869
 eGFR; MD, n 1 1 0  
 Mean, mL/min (SD)
Range
46.4 (14.4)
10–77
46.7 (15.3)
10–60
46.0 (13.5)
20–77
0.834
Charlson comorbidity index; median 
(IQR)
Range
7 (6, 8)
2–14
7 (6, 8)
2–14
8 (6, 9)
4–12
0.029*
Cardiac medication, n (%)
 ACE inhibitor 28 (36.4) 12 (27.9) 16 (47.1) 0.099
 ARB 11 (14.3) 6 (14.0) 5 (14.7) 1.000
 Beta-blocker 47 (61.0) 21 (48.8) 26 (76.5) 0.019
 Aldosterone blocker 25 (35.7) 18 (48.6) 7 (21.2) 0.024
 Aldosterone blocker: spironolactone 21 (27.3) 15 (34.9) 6 (17.6) 0.124
 Aldosterone blocker: eplerenone 4 (5.2) 3 (7.0) 1 (2.9) 0.626
CTG: caring together group; UCG: usual care group; MD: missing data; SD: standard deviation; N: number; SIMD: standardised index of multiple 
deprivation; HF: heart failure; IQR: inter-quartile range; NYHA: New York Heart Association; LVSD: left ventricular systolic dysfunction; eGFR: 
estimated glomerular filtration rate; ACE: angiotensin-converting enzyme; ARB: angiotensin II receptor blocker.
*Wilcoxon–Mann–Whitney test.
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What this study adds
This study provides useful feasibility and early safety data; 
the UCG did not appear to be disadvantaged in terms of 
survival or 4-month outcomes. Willingness to be ran-
domised was not tested but could be built into a pilot 
embedded into a phase III trial. Recruitment appeared to 
be easier from patients known to the research team (UCG). 
This should be taken into account when researchers are 
dependent on other clinical teams to identify potential par-
ticipants although eligible patients may be more inclined 
to participate in an intervention trial.
A recent US statement7 encourages problem-driven pal-
liative care independent of prognosis, citing benefits as 
improved patient/carer understanding, symptoms/suffer-
ing relief, patient-centred decision-making, improved 
communication, better ACP and bereavement support. 
Although the study was not designed to assess effective-
ness, the data on patient understanding, ACP documenta-
tion, fewer nights in hospital and being shifted from 
secondary to community care show promise – consistent 
with Component 5 (Box 1).
Conclusion
A clinical trial investigating the cost-effectiveness of car-
diology-led heart failure palliative care is feasible. A future 
trial should recruit from usual community-based care 
Table 5. Baseline outcome measures.
No missing data All, N = 77 CTG, N = 43 UCG, N = 34 P value
Health status and quality of life
 EQ-5D score, mean (SD)
Range
0.524 (0.288)
–0.170 to 0.951
0.517 (0.318)
–0.170 to 0.951
0.532 (0.250)
–0.027 to 0.951
0.828
 EQ-5D VAS, mean (SD)
Range
55.2 (26.0)
5 to 100
50.5 (26.8)
5 to 99
61.2 (24.0)
10 to 100
0.070
 KCCQ-12 score, mean (SD)
Range
37.36 (26.47)
0 to 100
35.37 (25.57)
0 to 88
39.89 (27.75)
0 to 100
0.465
Symptoms
 ESAS-r score, mean (SD)
Range
39.81 (21.14)
0 to 82
43.45 (21.56)
4 to 82
35.21 (19.96)
0 to 78
0.087
 HADS–anxiety, mean (SD)
Range
7.7 (5.3)
0 to 20
7.8 (4.9)
0 to 19
7.5 (5.9)
0 to 20
0.786
 HADS–depression, mean (SD)
Range
7.8 (4.5)
0 to 17
8.5 (4.6)
0 to 17
6.9 (4.4)
0 to 16
0.140
Caregivers
 Zarit caregiver, mean (SD)
Range
11.0 (5.3)
0 to 20
11.2 (5.3)
0 to 19
10.6 (5.8)
2 to 20
0.820
Understanding and advance care planning
Patients’ understanding of care, n (%)
 Not at all 5 (6.5) 1 (2.3) 4 (11.8) 0.003*
 A little 32 (41.6) 14 (32.6) 18 (52.9)  
 Fairly well 24 (31.2) 15 (34.9) 9 (26.5)  
 Very well 15 (19.5) 12 (27.9) 3 (8.8)  
 Completely 1 (1.3) 1 (2.3) 0 (0.0)  
DNAR-CPR: Evidence of discussion with 
patient in case notes, n (%)
38 (49.4) 33 (76.7) 5 (14.7) <0.001
DNAR-CPR: Evidence of discussion with 
carer in case notes, n (%)
24 (31.2) 22 (51.2) 2 (5.9 0.001
Documented ACP discussion (patient), n (%) 35 (45.5) 29 (67.4) 6 (17.6) 0.001
Documented ACP discussion (carer), n (%) 26 (33.8) 23 (53.5) 3 (8.8) <0.001
Documented preferred place of care, n (%)
 Home 30 (85.7) 25 (86.2) 5 (83.3) 0.634*
 Care home 0 (0.0) 0 (0.0) 0 (0.0)  
 Hospital 4 (11.4) 3 (10.3) 1 (16.7)  
 Hospice 1 (2.9) 1 (3.4) 0 (0.0)  
CTG: caring together group; UCG: usual care group; SD: standard deviation; N: number; EQ-5D: EuroQol-5 dimension scale; ESAS-r: Edmonton 
Symptom Assessment Scale – revised; KCCQ-12: Kansas City Cardiomyopathy Questionnaire; HADS: Hospital Anxiety and Depression Scale; 
DNAR-CPR: do not attempt cardiopulmonary resuscitation; ACP: anticipatory care plan.
*Wilcoxon–Mann–Whitney test.
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eligible for but not referred to cardiology palliative care, 
and identify those needing more intensive palliative care.
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